Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Harter, P; Pautier, P; Van Nieuwenhuysen, E; Reuss, A; Redondo, A; Lindemann, K; Kurzeder, C; Petru, E; Heitz, F; Sehouli, J; Degregorio, N; Wimberger, P; Burges, A; Cron, N; Ledermann, J; Lorusso, D; Paoletti, X; Marme, F.
Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34).
Int J Gynecol Cancer. 2020; 30(12): 1997-2001. Doi: 10.1136/ijgc-2020-001572
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Petru Edgar
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Improvement in clinical outcomes of patients with platinum-resistant disease is an unmet medical need and trials in this population are urgently needed. Checkpoint-inhibitors have already shown activity in multiple other tumor entities and ovarian cancer, especially in the combination with anti-angiogenic treatment. To test if the activity of non-platinum-based chemotherapy and bevacizumab could be improved by the addition of atezolizumab. The addition of atezolizumab to standard non-platinum combination of chemotherapy and bevacizumab improves median overall survival from 15 to 20 months. Patients are randomized to chemotherapy (paclitaxel weekly or pegylated liposomal doxorubicin) + bevacizumab + placebo vs chemotherapy + bevacizumab + atezolizumab. Stratification factors are: number of prior lines, planned type of chemotherapy, prior use of bevacizumab, and tumor programmed death-ligand 1 (PD-L1) status. Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer with up to three prior therapies and a treatment-free interval after platinum of less than 6 months. Patients with three prior lines of chemotherapy are eligible irrespective of the platinum free-interval. A de novo tumor tissue sample biopsy for determination of PD-L1 status prior to randomization for stratification is mandatory. Major exclusion criteria consider bevacizumab-specific and immunotherapy-specific criteria. Overall survival and progression-free survival are co-primary endpoints. It is planned to randomize 664 patients. NCT03353831. © IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Find related publications in this database (Keywords): ovarian cancer